Our Events Schedule Plan - Program

Our Events Schedule Plan

17Sept. 2025
13.25-13.30 pm - Opening
Welcome and introduction: Eric Deutsch, phD, MD
Director of Gustave Roussy Radiation Oncology Department and INSERM UMR 1030

13.25-13.30 pm: OPENING
Welcome and introduction
PRIMER ON RADIATIONS, CANCER IMMUNOLOGY AND IMMUNOTHERAPY

13.30-15.30 Session I:
Cancer immunology and Immunotherapy
(Oliver Kepp)
13.30-14.00: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
Pr Tim Illidge
Manchester Cancer Research Center, UK
14.00-14.30: Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Dr Lisa Derosa
Gustave Roussy, FR

14.30-15.00: Immune Metabolism,
Pr Guido Kroemer
Cordeliers Research Center, FR

15.00-15.30: Immunogenic cell death and autophagy,
Dr Lorenzo Galluzzi
Fox Chase Cancer Center, USA

15.30-16.00: Coffee break and exhibition
16.00-18.00 Session II:
Radiation dose, modalities and resistance
(François de Kermengy)
16.00-16.30: Charged particles radiotherapy,
Pr Marco Durrante
German Cancer Research Center, G
16.30-17.00: TBD
17.00-17.30: Next generation approaches in radiotherapy,
Pr Amir Abdollahi
NCT Heidelberg, G
17.30-18.00: Fatty acid metabolism and radiation-induced anti-tumor immunity,
Dr Claire Vanpouille-Box
Weill Cornell Medicine, USA
18.00-20.00
Cocktail poster session and exhibition
18Sept. 2025
MAIN PROGRAM
8.30-10.00 Session III:
Myeloid cells
(Paul Bergeron)
8.30-9.00: Sepsis-trained macrophages promote antitumoral tissue-resident T cells,
Pr Antoine Roquilly
Nantes University, FR
9.00-9.30: TBD
9.30-10.00: Dendritic cells as shepherds of T cell immunity in cancer,
Dr Mikael Pittet
University of Geneva, SW
10.00-10.30 Coffee break and exhibition
10.30-12.30 Session IV:
Immunosuppression
(Michele Mondini)
10.30-11.00: Microenvironmental reorganization in brain tumors following radiotherapy and recurrence revealed by hyperplexed immunofluorescence imaging,
Pr Johanna Joyce
University of Lausanne, SW
11.00-11.30: Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer,
Dr Fatima Mechta-Grigoriou
Institut Curie, FR
11.30-12.00: Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1,
Dr Monica Olcina
University of Oxford, UK
12.00-12.30: Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites,
Pr Ralph Weichselbaum
Chicago University, USA
12.30-14.00 Lunch break and exhibition
14.00-16.00 Session V:
DNA damage
(Marco)
14.00-14.30: The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy,
Pr Sandra Demaria
Weill Cornell Medicine, USA
14.30-15.00: Single-cell Transcriptome Profiling of Post-treatment and Treatment-naïve Colorectal Cancer: Insights into Putative Mechanisms of Chemoresistance
Dr Sergey Nikolaev
Gustave Roussy, FR
15.00-15.30: T-cell receptor determinants of response to chemo-radiation in locally-advanced HPV16-driven malignancies,
Pr Kevin Harrington
ICR, UK
15.30-16.00: Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING,
Dr Crispin Hiley
UCL Cancer Institute
16.00-16.30 coffee break and exhibition
16.30-18.00 Session VI:
Next generation Immunotherapy
(Marie Morfouace)
16.30-17.00: Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma,
Dr Jerome Galon
Cordeliers Research Center, FR
17.00-17.30: Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps
Pr Ignacio Melero
Clinica Universidad de Navarra, S
17.30-18.00: New immune-based approaches in the clinic,
Pr Fabrice Barlesi
Gustave Roussy, FR
20.00-00.00
Gala dinner
19Sept. 2025
8.30-10.0 Session VII:
Tumor Microenvironment
(Marine Fidelle/Carolina Alves Costa Silva)
8.30-9.00: Mechanisms regulating T-cell infiltration and activity in solid tumors,
Pr George Coukos
CHUV, SW
9.00-9.30: Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease,
Pr Martin Pruschy
University Hospital Zurich
9.30-10.00: TBD
10.00-10.30 Coffee break and exhibition
10.30-12.30 Session VIII:
AI, Imaging and Radiomics
(Ibrahim Bouakka)
10.30-11.00: First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET,
Pr Idris Bahce
VUMC, NL
11.00-11.30: Translational frontiers and clinical opportunities of immunologically-fitted radiotherapy,
Pr Eric Deutsch
Gustave Roussy, FR
11.30-12.00: Interventional Radiology For Cancer Immunotherapy: past, present and future,
Pr Lambros Tselikas
Gustave Roussy, FR
12.00-12.30: Using AI tools for precision medicine and immunotherapy,
Pr Fabrice André
Gustave Roussy, FR
12.30-14.00 Lunch break and exhibition
14.00-16.00 Session IX:
Adaptive Immunity
(Pierre-Antoine Laurent)

14.00-14.30: Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality,
Pr Laurence Zitvogel
Gustave Roussy, FR
14.30-15.00: Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Dr Maria Esperanza Rodriguez Ruiz
Clinica Universidad de Navarra, S
15.00-15.30: Emerging evidence for adapting radiotherapy to immunotherapy,
Pr Silvia Formenti,
Weill Cornell Medicine, USA
15.30-16.00: TBD
16.00-16.30 Coffee break and exhibition
16.30-18.00 Session X:
Innate Immunity
(Lydia Meziani)

16.30-17.00: Nuclear Medicine at the era of AI and Precision Oncology,
Dr Desirée Deandreis
Gustave Roussy, FR
17.00-17.30: TBD
17.30-18.00: TBD